What records are connected here?
- Evidence lanes
- 1
- Source years
- 1
- Drugs@FDA applications
- 0
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Not FDA-approved1,6Evidence: Animal and lab onlyNot a peptideHormones
Also called Long R3 IGF-I, Long-(Arg3) insulin-like growth factor-I1
Not a peptide: a protein, larger than a peptide, often looked up alongside peptides.
IGF-1 LR3 is a lab-made version of the growth factor IGF-1 (insulin-like growth factor 1): 83 amino acids, which makes it a protein under FDA’s definition, not a peptide.1,2 It was made in the early 1990s as a research tool. Changing one amino acid and adding a short extension changed how it binds to IGF-binding proteins, and it acted more strongly than natural IGF-1 on several kinds of cells in the laboratory.3,4 No study in people and no FDA approval are reported in the sources reviewed here, and it is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.5,6,8
| Substance type | Not a peptide. FDA’s substance registry records IGF-1 LR3 as a protein of 83 amino acids, and FDA’s 2020 rule defines a protein as a chain of more than 40 amino acids.1,2 |
|---|---|
| What it is | Human IGF-1 with arginine in place of glutamic acid at position 3 and a 13-amino-acid extension at the start, 83 amino acids in all, according to FDA’s substance registry.1 |
| FDA status | No FDA approval is reported in the sources reviewed here. FDA’s compounding safety-risk page does not list it.1,6 |
| Human evidence | None found. A 2010 report by doping-control researchers states that the effects of a tagged form of it in humans have not been described.5 |
| Evidence strength | Animal and lab studies only. The cited sources report no completed human study; the research base consists of animal, cell, or other laboratory work. How this label is assigned |
IGF-1 LR3, or long-(Arg3) insulin-like growth factor-I, is an engineered form of human IGF-1. FDA’s substance registry records it as a protein of 83 amino acids: IGF-1 with arginine at position 3, joined to a 13-amino-acid extension from pig growth hormone.1
FDA’s 2020 rule defines a protein as a chain of more than 40 amino acids, so at 83 amino acids IGF-1 LR3 counts as a protein, not a peptide.1,2
The 1992 study found that IGF-1 analogues with the added extension and the arginine-3 change were more potent than IGF-1 in cells that release IGF-binding proteins, and concluded that the gain came from changes in how they interact with those binding proteins.3
A 2025 study describes IGF-1 LR3 as an IGF-1 analogue with low affinity for IGF-binding proteins and high affinity for the IGF-1 receptor.4
None of the sources reviewed here describes a study of IGF-1 LR3 in people. A 2010 report by doping-control researchers, who identified a tagged form of it by mass spectrometry, states that its effects in humans have not been described.5
In growth-restricted fetal sheep, a week of IGF-1 LR3 did not improve growth, and it lowered amino acid levels in the blood, according to the 2025 study.4
Evidence-strength label: Animal and lab studies only. How this label is assigned
None of the sources reviewed here reports an approval of IGF-1 LR3 by FDA.1,6
FDA’s compounding safety-risk page, current as of April 22, 2026, does not list IGF-1 LR3.6
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. IGF-1 LR3 is not among them.7,8
Its effects and safety in people, which the sources reviewed here do not describe.5
How findings in cells and sheep relate to people: the 1992 study used laboratory cells, and the 2025 study treated fetal sheep for one week.3,4
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for IGF-1 LR3: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for IGF-1 LR3 are a bounded selection, not every registration or paper about IGF-1 LR3. For the years before IGF-1 LR3 was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list IGF-1 LR3 as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name IGF-1 LR3 in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
No FDA approval reported; studied only in cells and animals. Evidence comes from cell and animal studies; doping-control researchers state that its effects in humans have not been described. IGF-1 LR3 is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗↗↗
Status sources checked through November 14, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
No FDA approval reported; studied only in cells and animals. Evidence comes from cell and animal studies; doping-control researchers state that its effects in humans have not been described. IGF-1 LR3 is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗↗↗
The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Literature metadata · source date November 21, 2013
Detection of His-tagged Long-R³-IGF-I in a black market product.↗Added to PeptideScanner November 16, 2026Literature metadata · added November 16, 2026
Detection of His-tagged Long-R³-IGF-I in a black market product.↗Source date November 21, 2013PeptideScanner currently has no selected clinical trial records, regulatory records, and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
0 of 0 selected trial records include at least one phase value; 0 of 0 include a status value in the retained structured contract.
1 of 1 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PubMed lists PMID 20675162 in Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2010-08-02 (day precision). PeptideScanner associated the retained record with the identity slug igf-1-lr3. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
1 with attributed title, venue, publication-date, and type metadata.
Selected records span November 21, 2013 to November 21, 2013. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Literature metadata
PubMed lists PMID 20675162 in Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2010-08-02 (day precision). PeptideScanner associated the retained record with the identity slug igf-1-lr3. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
FDA Global Substance Registration System · Official source · Source checked November 16, 2026
Federal Register · Official source · Source checked November 16, 2026
Journal of Molecular Endocrinology · Official source · Source checked November 16, 2026
American Journal of Physiology. Endocrinology and Metabolism · Official source · Source checked November 16, 2026
Growth Hormone & IGF Research · Official source · Source checked November 16, 2026
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026